FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $3.91 |
|
$7.55 | $0.47 | -22.0 |
$4.50 |
|
| AT1 | $0.02 | 0.00% | $0.05 | $0.02 |
|
||
| AVE | $0.02 | 0.00% | $0.03 | $0.01 |
|
||
| BB1 | $0.67 |
|
$1.11 | $0.48 |
$1.76 |
|
|
| BRN | $0.14 |
|
$0.27 | $0.11 |
|
||
| CAT | $3.61 |
|
$7.72 | $2.74 |
$5.134 |
|
|
| CBL | $0.06 | 0.00% | $0.10 | $0.03 |
|
||
| CGS | $2.74 |
|
$3.01 | $1.65 | 29.8 |
$3.70 |
|
| CMP | $0.23 | 0.00% | $0.45 | $0.22 |
|
||
| COH | $133.93 |
|
$313.27 | $88.74 | 28.6 |
$114.028 |
|
| CSX | $0.40 | 0.00% | $0.85 | $0.32 |
|
||
| CTE | $1.25 |
|
$1.31 | $0.74 |
|
||
| CU6 | $2.80 |
|
$5.87 | $1.80 |
$6.40 |
|
|
| CVB | $0.02 | 0.00% | $0.18 | $0.02 |
|
||
| EBR | $0.30 |
|
$1.47 | $0.24 |
$1.585 |
|
|
| EIQ | $1.60 |
|
$1.88 | $0.17 |
$1.867 |
|
|
| EMV | $1.73 |
|
$2.43 | $1.47 |
$3.15 |
|
|
| EYE | $0.16 | 0.00% | $0.21 | $0.10 |
|
||
| FPH | $35.26 |
|
$35.92 | $26.51 | 13.6 |
|
|
| IME | $0.32 | 0.00% | $0.47 | $0.22 | 15.2 |
$0.50 |
|
| IMR | $2.05 |
|
$2.25 | $1.28 |
$2.90 |
|
|
| IPD | $0.01 | 0.00% | $0.06 | $0.00 |
$0.015 |
|
|
| LDX | $0.12 | 0.00% | $0.33 | $0.08 |
$0.25 |
|
|
| MX1 | $0.03 | 0.00% | $0.12 | $0.03 |
$0.08 |
|
|
| NAN | $3.55 |
|
$4.77 | $2.94 | 63.4 |
$3.80 |
|
| ONE | $0.16 | 0.00% | $0.41 | $0.13 |
$0.42 |
|
|
| PCK | $0.10 |
|
$0.35 | $0.04 |
|
||
| PEB | $0.22 | 0.00% | $0.27 | $0.09 |
|
||
| PGC | $0.13 | 0.00% | $0.41 | $0.13 | 10.0 |
$0.25 |
|
| PME | $183.71 |
|
$324.49 | $107.75 | 124.1 |
$221.667 |
|
| RAP | $0.03 | 0.00% | $0.07 | $0.02 |
|
||
| RMD | $31.80 |
|
$45.25 | $25.50 | 17.9 |
$38.875 |
|
| SHG | $0.19 | 0.00% | $0.36 | $0.17 |
|
||
| SOM | $0.37 |
|
$0.95 | $0.37 | 23.1 |
$0.75 |
|
| TRJ | $0.19 | 0.00% | $0.95 | $0.19 | 10.3 |
$0.825 |
|
-5.10% 
15.1% Previous Stories
Acquisition Loads Up Catapult
Oct 20 2025
In its latest acquisition, Catapult Sports has added the missing element to make it a globally competitive sports software company
Cochlear’s Future In Nexa’s Hands
Aug 19 2025
Following a weak FY25, and weak FY26 guidance, Cochlear’s outlook rests on the success of its new Nexa implant and other products. Is the market too confident?
ResMed’s New Level Of Support
Jul 29 2025
Michael Gable of Fairmont Equities reports buying the dip remains a valid strategy for ResMed shares above new technical support of $40
Strength To ‘AI’ Strength For Pro Medicus
Jul 10 2025
Pro Medicus shares surge on major contract wins and growing AI momentum, reinforcing its position as a high-margin healthcare tech leader against a background of eternal valuation debate
Cochlear Downgrades Ahead Of New Launches
Jun 19 2025
A decline in Services revenue had led to another profit downgrade from Cochlear, but brokers look ahead to new product launches
Fisher & Paykel Healthcare’s Tariffs Annoyance
Jun 04 2025
A consensus-beating FY25 result from Fisher & Paykel Healthcare was undermined by disappointing FY26 guidance, with tariffs partly to blame
ResMed’s Margin Expansion & Tariff Exemption
Apr 28 2025
ResMed’s largely in-line third quarter results showcased a rising gross margin, while management also moved to ease market concerns regarding tariffs
Trend Remains Up For Catapult International
Feb 18 2025
Michael Gable of Fairmont Equities sees an ongoing uptrend for shares in Catapult Group International
ESG Focus: Top ASX Companies, Superbugs & Hydrogen
Feb 07 2025
Addressing challenges and opportunities in meeting the UN Sustainable Development Goals and what ESG characteristics underpin share prices
ResMed Shakes Off GLP-1 Scare
Feb 04 2025
The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry